Methods of screening for a compound that reduces atherogenesis
US8691498B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2006 |
| Grant date | Apr 8, 2014 |
| Priority date | — |
| Expiry date | Oct 21, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/323
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.